HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study.

AbstractINTRODUCTION:
Interleukin-6 receptor (IL-6R) blockade improves the signs and symptoms of rheumatoid arthritis (RA) and retards bone damage. Whether IL-6R blockade allows repair of existing bone erosions is so far unclear.
METHODS:
This study examined bone erosions in the metacarpophalangeal joints of 20 patients receiving treatment with the IL-6R blocker tocilizumab using micro CT (µCT). The maximal width and depth of individual bone erosions was measured at baseline and after 1 year of treatment.
RESULTS:
133 bone erosions were identified at baseline with a mean (±SD) size of 2.23±1.26 mm and depth of 2.16±1.50 mm. Distribution analysis showed predominant involvement of the second compared with the third and fourth metacarpophalangeal joints, the metacarpal heads compared with the phalangeal bases and the radial quadrants compared with all other surfaces. Repair of bone erosions during tocilizumab treatment was confined to those lesions showing sclerosis at baseline and/or at follow-up and those with a width larger than 1.6 mm. The mean decrease in width of sclerosed erosions was thus 0.14±0.05 mm (p=0.0086) and 0.20±0.08 mm (p=0.019) for sclerosing lesions after 1 year of treatment.
CONCLUSIONS:
Blockade of IL-6R by tocilizumab can induce limited repair in a subset of erosions, particularly in large lesions with sclerosis. Repair of erosions during tocilizumab treatment reflects the favourable impact of IL-6R blockade on local bone remodelling in patients with RA.
AuthorsStephanie Finzel, Juergen Rech, Sarah Schmidt, Klaus Engelke, Matthias Englbrecht, Georg Schett
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 72 Issue 3 Pg. 396-400 (Mar 2013) ISSN: 1468-2060 [Electronic] England
PMID22586162 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Receptors, Interleukin-6
  • tocilizumab
  • Methotrexate
Topics
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Antirheumatic Agents (administration & dosage)
  • Arthritis, Rheumatoid (diagnostic imaging, drug therapy, pathology)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Metacarpophalangeal Joint (diagnostic imaging, pathology)
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Receptors, Interleukin-6 (antagonists & inhibitors)
  • X-Ray Microtomography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: